1,400个基因预测的血代谢物与原发性胆道胆道炎风险有关:双向,双样本的门德尔随机化分析
Wenqian Geng1,2, Xiajie Wen1,2, Ronghua Jin1,2
1Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Clinical and experimental hepatology
|April 30, 2025
概括
这项研究研究了原发性胆道胆炎 (PBC) 的血代谢物. 发现四种代谢物因果影响PBC风险,为诊断和治疗提供了潜在的新途径.
科学领域:
- 代谢学 代谢学 代谢学
- 肝病学 肝病学是一种肝病学.
- 遗传流行病学遗传流行病学
背景情况:
- 初级胆道胆炎 (PBC) 是一种自身免疫性肝脏疾病.
- 血代谢物是关键的生理指标,但它们在PBC病原发生中的作用尚不清楚.
研究的目的:
- 通过强有力的分析方法,研究1400种血代谢物和PBC之间的因果关系.
- 确定可能影响PBC风险或进展的特定代谢物.
主要方法:
- 进行了两样本的门德尔随机化 (MR) 分析.
- 使用了代谢物和PBC的全基因组关联研究数据.
- 反变量加权 (IVW) 方法是主要的分析工具,用于验证的灵敏度分析.
主要成果:
- 四种血代谢物与PBC有显著的因果关联.
- 斯芬哥辛1-酸盐和多科沙酸盐与降低PBC风险有关.
- 荷马阿尔吉宁和坎普斯特罗尔与增加PBC风险有关.
结论:
- 这项MR研究确定了四种血代谢物,在PBC发育中具有潜在的因果作用.
- 这些发现表明PBC预后和潜在治疗点的新生物标志物.
- 没有证据表明PBC和已识别的代谢产物之间存在逆因果关系.
相关概念视频
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


